Skip to main content
SpringerLink
Log in

Cardiotoxicity of Commonly Used Drugs in HSCT

  • Chapter
  • First Online:
Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation

  • 20 Accesses

Abstract

Many drugs used in hematopoietic stem cell transplantation (HSCT) settings have the potential to cause adverse cardiovascular effects. Drug-induced cardiotoxicity is a serious adverse effect with a high rate of morbidity and mortality in patients undergoing autologous or allogeneic HSCT. The mechanism of drug-induced cardiotoxicity can involve direct or indirect damage to cardiac cells. Furthermore, these toxicities may manifest either early or late. There are several risk factors that can increase an individual’s susceptibility to cardiotoxicity. Identifying prevention and management strategies for cardiac complications induced by drugs is crucial.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ADR:

Adverse drug reaction

BMT:

Bone marrow transplant

Cap:

Capsule

CYP450:

Cytochrome P450

DR:

Delayed-release

ECG:

Electrocardiogram

EF:

Ejection fraction

ER:

Extended-release

GVHD:

Graft-versus-host disease

HSCT:

Hematopoietic stem cell transplant

IM:

Intramuscular

Inj:

Injection

IV:

Intravenous

Susp:

Suspension

Tab:

Tablet

TDM:

Therapeutic drug monitoring

TdP:

Torsade points

References

  • Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. The Lancet. 2001;357(9270):1766–7.

    Article  CAS  Google Scholar 

  • Airey C, Dodwell D, Joffe J, Jones W. Etoposide-related myocardial infarction. Clin Oncol. 1995;7(2):135.

    Article  CAS  Google Scholar 

  • Alidina A, Lawrence D, Ford L, Baer MR, Bambach B, Bernstein SH, et al. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Biol Blood Marrow Transp. 1999;5(5):322–7.

    Article  CAS  Google Scholar 

  • Alkan Y, Haefeli W, Burhenne J, Stein J, Yaniv I, Shalit I. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. Clin Infect Dis. 2004;39(6):e49–52.

    Article  CAS  PubMed  Google Scholar 

  • Angelucci E, Lucarelli G, Baronciani D, Durazzi S, Galimberti M, Giardini C, et al. Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. The Lancet. 1992;339(8788):287–9.

    Article  CAS  Google Scholar 

  • Appelbaum F, Strauchen J, Graw JRR, Savage D, Kent K, Ferrans V, et al. Acute lethal carditis caused by high-dose combination chemotherapy: a unique clinical and pathological entity. The Lancet. 1976;307(7950):58–62.

    Article  Google Scholar 

  • Ashley ED, Perfect J. Pharmacology of azoles. UpToDate. In: Kauffman CA, editor. UpToDate. Waltham, MA; 2017

    Google Scholar 

  • Atkison P, Joubert G, Barron A, Grant D, Wall W, Rosenberg H, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. The Lancet. 1995;345(8954):894–6.

    Article  CAS  Google Scholar 

  • Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553–64.

    Article  CAS  PubMed  Google Scholar 

  • Bearman S, Petersen F, Schor R, Denney J, Fisher L, Appelbaum F, et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transp. 1990;5(3):173–7.

    CAS  Google Scholar 

  • Bidaki R, Kian M, Owliaey H, Zarch MB, Feysal M. Accidental chronic poisoning with methotrexate; report of two cases. Emergency. 2017;5(1)

    Google Scholar 

  • Birchall I, Lalani Z, Venner P, Hugh J. Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy. Br J Radiol. 2000;73(874):1112–4.

    Article  CAS  PubMed  Google Scholar 

  • Bleeker J, Gertz M, Pellikka P, Buadi F, Dingli D, Dispenzieri A, et al. Cardiomyopathy following high dose melphalan conditioning prior to autologous peripheral blood stem cell transplantation for multiple myeloma and primary amyloidosis. Biol Blood Marrow Transp. 2011;17(2):S203.

    Article  Google Scholar 

  • Brockstein B, Smiley C, Al-Sadir J, Williams S. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transp. 2000;25(8):885–94.

    Article  CAS  Google Scholar 

  • Choi SW, Reddy P. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol. 2014;11(9):536–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chou H-W, Wang J-L, Chang C-H, Lai C-L, Lai M-S, Chan KA. Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study. Clin Infect Dis. 2015;60(4):566–77.

    Article  CAS  PubMed  Google Scholar 

  • Cleary JD, Stover KR, Farley J, Daley W, Kyle PB, Hosler J. Cardiac toxicity of azole antifungals; 2013

    Google Scholar 

  • Dhesi S, Chu MP, Blevins G, Paterson I, Larratt L, Oudit GY, et al. Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management. J Investigat Med High Impact Case Rep. 2013;1(1):2324709613480346.

    Google Scholar 

  • Elazhary S, Alawyat HA. Bradycardia associated with antithymocyte globulin treatment of a pediatric patient with sickle cell disease: a case report and literature review. Hematol Transfus Cell Ther. 2022;44:284–7.

    Article  PubMed  Google Scholar 

  • Elewa H, El-Mekaty E, El-Bardissy A, Ensom MH, Wilby KJ. Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: a critical review. Clin Pharmacokinet. 2015;54:1223–35.

    Article  CAS  PubMed  Google Scholar 

  • Feliz V, Saiyad S, Ramarao SM, Khan H, Leonelli F, Guglin M. Melphalan-induced supraventricular tachycardia: Incidence and risk factors. Clin Cardiol. 2011;34(6):356–9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475–87.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gill D, Mann K, Kaur S, Ruiz V, Dean R. Rare cause of cardiotoxicity Arch Med. 2017;9:1.

    CAS  Google Scholar 

  • Godown J, Deal AM, Riley K, Bailliard F, Blatt J. Worsening bradycardia following antithymocyte globulin treatment of severe aplastic anemia. J Pediat Pharm Therapeut. 2011;16(3):218–21.

    Article  Google Scholar 

  • Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, et al. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf. 2019;42:529–38.

    Article  CAS  PubMed  Google Scholar 

  • Hernández Silva G, Puerto Chaparro RG, Martínez Melo JÁ, Porras Bueno CO, Martínez Rodríguez JE, González Trillos SJ. Hypertrophic cardiomyopathy secondary to tacrolimus therapy in a kidney transplant patient: a case report and focused review of the literature. Clinical Case Rep. 2022;10(11): e6539.

    Article  Google Scholar 

  • Hodak SP, Moubarak JB, Rodriguez I, Gelfand MC, Alijani MR, Tracy CM. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. Transplant. 1998;66(4):535–7.

    Article  CAS  Google Scholar 

  • Hoffmann WJ, McHardy I, Thompson GR III. Itraconazole induced hypertension and hypokalemia: mechanistic evaluation. Mycoses. 2018;61(5):337–9.

    Article  CAS  PubMed  Google Scholar 

  • Jana AK, Praharaj SK, Roy N. Olanzapine-induced orthostatic hypotension. Clin Psychopharmacol Neurosci. 2015;13(1):113.

    Article  PubMed  PubMed Central  Google Scholar 

  • Jones RB. Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. Clin. Relev. Resis. Cancer Chemo. 2002:305–22

    Google Scholar 

  • Kamezaki K, Fukuda T, Makino S, Harada M. Cyclophosphamide-induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation. Intern Med. 2005;44(2):120–3.

    Article  PubMed  Google Scholar 

  • Kang J, Wang L, Chen X-L, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59(1):122–6.

    Article  CAS  PubMed  Google Scholar 

  • Kanj SS, Sharara AI, Shpall EJ, Jones RB, Peters WP. Myocardial ischemia associated with high-dose carmustine infusion. Cancer. 1991;68(9):1910–2.

    Article  CAS  PubMed  Google Scholar 

  • Khatib R, Sabir FR, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452–8.

    Article  PubMed  Google Scholar 

  • Kockx M, Kritharides L. Cyclosporin A-induced hyperlipidemia. Lipoproteins-Role in Health and Diseases. Rijeka: InTech Publishers; 2012. pp. 337–54

    Google Scholar 

  • Kounis NG. Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? Int J Cardiol. 2006;110(1):7–14.

    Article  PubMed  Google Scholar 

  • Kuittinen T, Husso-Saastamoinen M, Sipola P, Vuolteenaho O, Ala-Kopsala M, Nousiainen T, et al. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin’s lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transp. 2005;36(12):1077–82.

    Article  CAS  Google Scholar 

  • Lee C, Harman G, Hohl R, Gingrich R. Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment. Bone Marrow Transp. 1996;18(3):573–7.

    CAS  Google Scholar 

  • Lee C-C, Lee M-G, Chen Y-S, Lee S-H, Chen Y-S, Chen S-C, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA internal medicine. 2015;175(11):1839–47

    Google Scholar 

  • Li M, Ramos LG. Drug-induced QT prolongation and torsades de pointes. Pharm Therapeut. 2017;42(7):473.

    Google Scholar 

  • Liu R, Li D, Sun F, Rampoldi A, Maxwell JT, Wu R, et al. Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells. Stem Cell Res Ther. 2020;11:1–17.

    Article  CAS  Google Scholar 

  • Lorraine I, John A. Physiologic and pharmacologic effects of corticosteroids. Holland-Frei Canc Med. 2013:34–67

    Google Scholar 

  • Mahal HS. Fluconazole-induced type 1 Kounis syndrome. Am J Ther. 2016;23(3):e961–2.

    Article  Google Scholar 

  • Mancano MA. ISMP adverse drug reactions: allergic angina caused by fluconazole rhabdomyolysis caused by risperidone high incidence of hyponatremia with high-dose trimethoprim-sulfamethoxazole lithium carbonate-induced hypersalivation persistent hemorrhage after idarucizumab administration. Hosp Pharm. 2017;52(7):455–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004;103(4):1557–9.

    Article  CAS  PubMed  Google Scholar 

  • McEvoy G, Miller J, Snow E. AHFS 2010 drug information. Bethesda, MD: American Society of Health-Systems Pharmacists Inc.; 2010.

    Google Scholar 

  • Mileshkin L, Seymour J, Wolf M, Gates P, Januszewicz E, Joyce P, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005;46(11):1575–9.

    Article  CAS  PubMed  Google Scholar 

  • Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transp. 2002;2(9):807–18.

    Article  CAS  Google Scholar 

  • Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky‐Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy: J. Human Pharmacol. Drug Therapy. 2008;28(5):614–45

    Google Scholar 

  • Morandi P, Ruffini P, Benvenuto G, La Vecchia L, Mezzena G, Raimondi R. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide. Bone Marrow Trans. 2001;28(3):277–82.

    Article  CAS  Google Scholar 

  • Nakamae H, Tsumura K, Hino M, Hayashi T, Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. The Lancet. 2000;355(9206):805–6.

    Article  CAS  Google Scholar 

  • Nakamae H, Hino M, Akahori M, Terada Y, Yamane T, Ohta K, et al. Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2004;76(1):1–7.

    Article  PubMed  Google Scholar 

  • Nakata Y, Yoshibayashi M, Yonemura T, Uemoto S, Inomata Y, Tanaka K, et al. Tacrolimus and myocardial hypertrophy. Transp. 2000;69(9):1960–2.

    Article  CAS  Google Scholar 

  • Negrin RS. Early complications of hematopoietic cell transplantation. UpToDate. 2020. https://www.uptodate.com/contents/earlycomplications-of…

  • Newbery G, de Alcantara LN, Gurgel LA, Driscoll R, Lima CC. Persistent heart failure following melphalan and fludarabine conditioning. J Cardiol Cases. 2019;20(3):88–91.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ng M, Celermajer D. Glucocorticoid treatment and cardiovascular disease. BMJ Publishing Group Ltd; 2004. pp. 829–30

    Google Scholar 

  • Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transp. 2000;6(2):198–203.

    Article  CAS  Google Scholar 

  • Nowis D, Mączewski M, Mackiewicz U, Kujawa M, Ratajska A, Wieckowski MR, et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol. 2010;176(6):2658–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ogino MH, Tadi P. Cyclophosphamide. 2020

    Google Scholar 

  • Pannuti F, Barboni F. Histopathological study of the heart-damaging effects of thio-tepa in the chick embryo “in situ”. 3. Quaderni Sclavo di diagnostica clinica e di laboratorio. 1972;8(2):669–78

    Google Scholar 

  • Patel R, Busulfan TP. StatPearls [Internet]: StatPearls Publishing; 2021

    Google Scholar 

  • Philips J, Marty F, Stone R, Koplan B, Katz J, Baden L. Torsades de pointes associated with voriconazole use. Transpl Infect Dis. 2007;9(1):33–6.

    Article  CAS  PubMed  Google Scholar 

  • Phillips GL, Meisenberg B, Reece D, Adams V, Badros A, Brunner J, et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transp. 2004;10(7):473–83.

    Article  CAS  Google Scholar 

  • Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. J Am Heart Assoc. 2017;6(12): e007724.

    Article  PubMed  PubMed Central  Google Scholar 

  • Qu Y, Fang M, Gao B, Amouzadeh HR, Li N, Narayanan P, et al. Itraconazole decreases left ventricular contractility in isolated rabbit heart: mechanism of action. Toxicol Appl Pharmacol. 2013;268(2):113–22.

    Article  CAS  PubMed  Google Scholar 

  • Raj SR, Stein CM, Saavedra PJ, Roden DM. Cardiovascular effects of noncardiovascular drugs. Circulation. 2009;120(12):1123–32.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ram R, Storb R. Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leuk Lymphoma. 2013;54(8):1591–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ritchie D, Seymour J, Roberts A, Szer J, Grigg A. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transp. 2001;28(1):101–3.

    Article  CAS  Google Scholar 

  • Saag KG, Furst DE. Major side effects of systemic glucocorticoids. 2012

    Google Scholar 

  • Sampat PJ, Riaz S, Martinez F, Aiello D. Bortezomib plus melphalan-induced cardiomyopathy presenting as sinus tachycardia and systolic heart failure. Cureus. 2020;12(7)

    Google Scholar 

  • Shah S, Haeger-Overstreet K, Flynn B. Methotrexate-induced acute cardiotoxicity requiring veno-arterial extracorporeal membrane oxygenation support: a case report. J Med Case Rep. 2022;16(1):447.

    Article  PubMed  PubMed Central  Google Scholar 

  • Shanholtz C. Acute life-threatening toxicity of cancer treatment. Crit Care Clin. 2001;17(3):483–502.

    Article  CAS  PubMed  Google Scholar 

  • Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother. 1991;35(4):707–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Singh S, Nautiyal A. Aortic dissection and aortic aneurysms associated with fluoroquinolones: a systematic review and meta-analysis. Am. J. Med. 2017;130(12):1449–57. e9

    Google Scholar 

  • Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf. 1999;20:437–49.

    Article  CAS  PubMed  Google Scholar 

  • Teaford HR, Saleh OMA, Villarraga HR, Enzler MJ, Rivera CG. The many faces of itraconazole cardiac toxicity. Mayo Clin Proceed: Innovat, Qual Outcom. 2020;4(5):588–94.

    Google Scholar 

  • Tricco AC, Soobiah C, Antony J, Hemmelgarn B, Moher D, Hutton B, et al. Safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery and chemotherapy: protocol for a systematic review and network meta-analysis. Syst Rev. 2013;2:1–5.

    Google Scholar 

  • Tuzovic M, Mead M, Young PA, Schiller G, Yang EH. Cardiac complications in the adult bone marrow transplant patient. Curr Oncol Rep. 2019;21:1–16.

    Article  Google Scholar 

  • Weinberger A, Pinkhas J, Sandbank U, Shaklai M, de Vries A. Endocardial fibrosis following busulfan treatment. JAMA. 1975;231(5):495

    Google Scholar 

  • Yanamandra U, Gupta S, Khadwal A, Malhotra P. Melphalan-induced cardiotoxicity: ventricular arrhythmias. Case Reports. 2016:bcr2016218652

    Google Scholar 

  • Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.

    Article  CAS  PubMed  Google Scholar 

  • Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, et al. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021;5(24):5599–607.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yuda S, Fuji S, Savani B, Gatwood KS. Antiemetic strategies in patients who undergo hematopoietic stem cell transplantation. Clin Hemat Inter. 2022;4(3):89–98.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Bita Shahrami

  2. Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Bita Shahrami & Mohammad Vaezi

Authors
  1. Bita Shahrami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Vaezi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Vaezi .

Editor information

Editors and Affiliations

  1. Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

    Azin Alizadehasl

  2. Cancer and Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Ardeshir Ghavamzadeh

  3. Hematology- Oncology Department, Cancer Institute, Tehran, Iran

    Amir Hossein Emami

  4. Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Ghasem Janbabaei

  5. Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

    Davood Khoda-Amorzideh

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shahrami, B., Vaezi, M. (2024). Cardiotoxicity of Commonly Used Drugs in HSCT. In: Alizadehasl, A., Ghavamzadeh, A., Emami, A.H., Janbabaei, G., Khoda-Amorzideh, D. (eds) Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation . Springer, Cham. https://doi.org/10.1007/978-3-031-53659-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-53659-5_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-53658-8

  • Online ISBN: 978-3-031-53659-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation